A Global Mission for Better Care
Why we do it
IPOPI is a non-profit international organisation and the leading advocate for patients living with primary immunodeficiencies (PID) and associated conditions worldwide, working in collaboration with patients, doctors, politicians, regulators, the pharmaceutical industry and other relevant stakeholders.
IPOPI is the Association of National PID patient organisations dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiency patients worldwide through global collaboration.
Our commitment
We are committed to driving meaningful change for the PID community through:
Championing policies that protect patient rights and expand access to diagnosis and treatment.
Raising public and professional awareness of primary immunodeficiencies to improve early diagnosis and understanding.
Working to ensure equitable access to diagnosis, treatment, and lifelong care for all PID patients worldwide.
Building partnerships across countries and organisations to share knowledge and strengthen the global PID community.
Strategic objectives
We are committed to driving meaningful change for the PID community through:
We advocate for strong, patient-centred policies that improve access to diagnosis, treatment, and long-term care for people living with primary immunodeficiencies. Through global engagement with policymakers and health authorities, we work to ensure that PID patients are heard, protected, and prioritised.
Providing education and resources for patients, families, healthcare professionals, and policymakers to build understanding of primary immunodeficiencies.
Supporting research initiatives and data collection to advance knowledge, improve outcomes, and inform evidence-based policy for the PID community.
Partnering with patient organisations, medical societies, and institutions worldwide to strengthen the global PID network and share best practices.
Take Action
See our work in action or support our mission. Together, we make a difference.